4.9 (207) In stock
Figure 1 from Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
2021 Update on Systemic Therapy for Breast Cancer Published in healthbook TIMES Oncology Hematology
A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy
Ivana SESTAK, Associate Professor in Medical Statistics
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Cumulative incidence rates for all breast cancers and invasive estrogen
JCM, Free Full-Text
Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer
A Novel Mathematical Approach for Analysis of Integrated Cell–Patient Data Uncovers a 6-Gene Signature Linked to Endocrine Therapy Resistance - Laboratory Investigation
Kaplan-Meier graphs for the disease-free and overall survival rates of
Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
